Bioxodes SA, a Marche-en-Famenne, Belgium-based developer of products derived from natural sources, completed a €2.6m (US$3.5m) in first seed funding round.
Backers included a consortium of business angels and Belgian investment funds while €1.6m came from the European Regional Development Fund (ERDF) and the Walloon Region in Belgium via the Retech program for Research and Technology.
The company intends to use the funds to bring its lead product Ir-CPI into pre-clinical development over the next 18 months.
Led by CEO and chief scientific officer Professor Edmond Godfroid, Bioxodes develops products derived from natural sources. The company is developing a portfolio of products with a wide range of beneficial healthcare applications in humans.
Its Ir-CPI is an antithrombotic derived from tick’s saliva, with the property of inhibiting clotting at doses which do not cause bleeding. It is potentially the world’s first injectable antithrombotic for use in all patient groups without causing high levels of bleeding.
Biodoxes has operations in the BioPark at Gosselies.